GET DAILY SIGNALSWhy Is Natera (NTRA) Stock Down -11.46% Today?
Key Takeaways
- Shares of NTRA fell roughly 11.46% on Friday, sliding from a prior close of $363.76 to about $322.09 in early trading.
- The primary catalyst was a wider-than-expected third-quarter loss, even though revenue beat forecasts and full-year guidance was raised.
- A surprise CEO transition compounded the selling, as longtime chief executive Steve Chapman handed the role to Solomon Moshkevich.
- Higher planned spending on SG&A and R&D signaled that profitability may remain elusive, pressuring the stock's premium valuation.
- Sector-wide weakness in liquid-biopsy and genetic-testing names added to the decline following a disappointing quarter from peer Grail.
- Traders are watching next for how the new leadership executes the 2026 revenue plan and whether the Signatera growth story continues.
- For more detail on analyst Price Targets, Earnings, and Forecast, explore these dedicated pages.
- Curious how AI trading strategies are positioning in real time? Visit Trending AI Robots to see the top-performing bots under current market conditions.
Opening Summary
Natera, Inc. (NTRA), the Austin, Texas-based cell-free DNA (cfDNA) and genetic-testing company known for its Signatera oncology test and Panorama prenatal screening, saw its shares plunge on Friday following its third-quarter 2026 earnings report. The stock dropped about 11.46%, trading near $322.09 after closing the prior session at $363.76 — a decline of roughly $41.67 per share. The selloff came despite a revenue beat and a guidance raise, as investors focused instead on a steeper-than-expected per-share loss, higher spending plans, and an unexpected change at the top of the company.
Earnings Beat on Revenue, Miss on Profitability
The quarter's headline numbers told a mixed story. Natera reported revenue of approximately $794 million, up about 34% year over year and comfortably above the roughly $707 million to $708 million that analysts had expected. The company also raised its full-year 2026 revenue guidance by about $140 million at the midpoint, to a range of $3.005 billion to $3.035 billion, and introduced a long-term target of $6 billion in revenue by 2029.
However, the bottom line disappointed. The company posted a GAAP net loss of $0.42 per share, significantly wider than the consensus estimate of roughly a $0.28 to $0.29 loss. The wider deficit reflected higher spending across research and development, commercial teams, and the biopharma business. In a market that had priced Natera for sustained outperformance, the earnings miss overshadowed the top-line strength and triggered an immediate repricing of the stock.
Surprise CEO Transition Adds Uncertainty
Compounding the earnings-driven decline, Natera announced that Steve Chapman, its chief executive for nearly eight years, would step down with immediate effect and transition to a consulting and advisory role. He is being succeeded by Solomon Moshkevich, who most recently served as president of the company's clinical diagnostics business and has been with Natera for roughly 15 years.
While the company characterized the change as occurring "from a position of strength" and signaled no major strategic shift, abrupt leadership transitions at a high-multiple growth company tend to inject uncertainty. Investors often reassess execution risk during such changes, which added to the selling pressure on Friday.
Rising Spending Plans Weigh on Sentiment
Alongside the results, Natera raised its operating-expense guidance. SG&A spending guidance was lifted to $1.225 billion–$1.300 billion from $1.125 billion–$1.225 billion, while R&D guidance was raised to $825 million–$925 million from $800 million–$900 million. Combined, the higher midpoint spending — roughly $113 million — reflects one-time costs, an expanded Signatera marketing push, and additional clinical trials.
For a company still reporting losses, the increase in planned spending reinforced concerns that profitability remains further out, even as the underlying growth story remains strong. Clinical volume for Natera's molecular residual disease (MRD) tests, including Signatera, rose about 56% year over year to roughly 316,000 units.
Sector Weakness and Broader Market Context
The decline in NTRA did not occur in isolation. The liquid-biopsy and genetic-diagnostics sector was already under pressure after Grail (GRAL) reported disappointing revenue and its shares fell sharply. Rival Guardant Health (GH) also reported a similar quarter and declined, reinforcing a broader reset across the group. Notably, major indices were mixed to modestly positive on the day, underscoring that the move in Natera was driven largely by company- and sector-specific factors rather than a broad market downturn.
Market Context and Trading Activity
Trading activity reflected the heavy repositioning. Natera entered the week trading near 17 times forward sales — well above its historical average and close to its five-year highs — leaving little room for disappointment. The post-earnings selloff pushed shares through key technical levels, undercutting the 50-day moving average and bringing the stock toward the 200-day line. Elevated volume accompanied the move as investors unwound positions in a stock that had been "priced for perfection" heading into the report.
What Comes Next for NTRA
Looking ahead, investors will focus on how the new leadership under Moshkevich executes against the raised 2026 revenue guidance and the ambitious $6 billion 2029 target. Near-term catalysts include Medicare reimbursement decisions for serial Signatera use in certain indications, additional MolDX submissions, potential Japanese approval in muscle-invasive bladder cancer, and the FIND colorectal screening readout expected in 2027. Key risks include the pace of spending versus revenue growth, competitive dynamics in cancer blood testing, and the market's willingness to pay a premium multiple for a company that remains unprofitable. Fourth-quarter results early next year will offer the first clear test of the transition.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-powered trading bots that are currently demonstrating strong performance. While Tickeron offers hundreds of bots covering thousands of tickers, only the strongest performers under current market conditions are featured in this section. These bots vary by strategy, timeframe, performance metrics, and the symbols they trade. Explore the page to see which automated strategies are leading right now.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
NTRA in upward trend: price may jump up because it broke its lower Bollinger Band on November 05, 2026
NTRA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 29 of 34 cases where NTRA's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a +3.20% 3-day Advance, the price is estimated to grow further. Considering data from situations where NTRA advanced for three days, in 246 of 310 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
Bearish Trend Analysis
The 10-day RSI Indicator for NTRA moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 39 similar instances where the indicator moved out of overbought territory. In 25 of the 39 cases, the stock moved lower in the following days. This puts the odds of a move lower at 64%.
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NTRA as a result. In 77 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.
The Moving Average Convergence Divergence Histogram (MACD) for NTRA turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 37 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 74%.
NTRA moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NTRA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 75%.
The Aroon Indicator for NTRA entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 6 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (28.786) is normal, around the industry mean (66.084). NTRA's P/E Ratio (-269.452) is considerably lower than the industry average of (2.723). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (17.857) is also within normal values, averaging (9.775).
The Tickeron Profit vs. Risk Rating rating for this company is 9 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. NTRA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 85 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a genetic testing company which develops proprietary bioinformatics-based technology
Industry MedicalSpecialties
Advertisement